Sandbox 55: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 54: | Line 54: | ||
In the normal catalytic mechanism of converting HMG-CoA to mevalonate, the carboxyl group of hydroxymethylglutarate that is in ester linkage to the thiol of coenzyme A is reduced twice via NADPH to an aldehyde and then to an alcohol. | In the normal catalytic mechanism of converting HMG-CoA to mevalonate, the carboxyl group of hydroxymethylglutarate that is in ester linkage to the thiol of coenzyme A is reduced twice via NADPH to an aldehyde and then to an alcohol. | ||
[[Image:HMGCR_mechanism.gif| | [[Image:HMGCR_mechanism.gif|right|thumb| HMG-CoA Reductase Mechanism ]] | ||
HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthesis pathway. Atorvastatin selectively and competitively inhibits HMG-CoA reductase. The inhibition subsequently increases the expression of LDL receptors on hepatocytes, which increases LDL uptake by hepatocytes, therefore decreasing the LDL-cholesterol concentration in the blood. Atorvastatin also increases levels of HDL-cholesterol.<ref>LDL-C, Decreasing. "DrugBank: Atorvastatin (DB01076)." DrugBank: Welcome. Web. 09 Mar. 2011. <http://www.drugbank.ca/drugs/DB01076>.</ref> | HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthesis pathway. Atorvastatin selectively and competitively inhibits HMG-CoA reductase. The inhibition subsequently increases the expression of LDL receptors on hepatocytes, which increases LDL uptake by hepatocytes, therefore decreasing the LDL-cholesterol concentration in the blood. Atorvastatin also increases levels of HDL-cholesterol.<ref>LDL-C, Decreasing. "DrugBank: Atorvastatin (DB01076)." DrugBank: Welcome. Web. 09 Mar. 2011. <http://www.drugbank.ca/drugs/DB01076>.</ref> | ||
